UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
May 14, 2013

Unigene Laboratories, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-16005	22-2328609
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

81 Fulton Street, Boonton, New Jersey		07005
(Address of principal executive offices)		(Zip Code)

(973) 265-1100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

This Form 8-K/A amends the Form 8-K that was filed by Unigene Laboratories Inc. on May 14, 2013 solely to move the disclosure to Item 2.02 - Results of Operations and Financial Condition.

Section 2 – Financial Information

Item 2.02 Results of Operations and Financial Condition.

On May 14, 2013, Unigene Laboratories, Inc. issued a press release announcing the financial results for the quarter ended March 31, 2013 and provided a corporate update on the Company’s financial condition and strategic initiatives. A copy of the press release is furnished as Exhibit 99.1 to this report.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

	Exhibit No.	Document Description
	99.1	Press Release dated May 14, 2013

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	UNIGENE LABORATORIES, INC.


	By:	/s/ Ashleigh Palmer
		Ashleigh Palmer, Chief Executive Officer



Date:May 17, 2013

Exhibit Index

	Exhibit No.	Document Description
	99.1	Press Release dated May 14, 2013

UNIGENE LABORATORIES INC 8-K/A